Cover Image
Read Now

Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)

The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, February 2018
Series:CADTH common drug review clinical review report
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01157nam a2200229 u 4500
001 EB002001037
003 EBX01000000000000001163938
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation)  |h Elektronische Ressource 
246 3 1 |a CADTH common drug review clinical review report for Maviret 
260 |a Ottawa (ON)  |b CADTH  |c 2018, February 2018 
300 |a 1 PDF file (112 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review clinical review report 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK533768  |3 Volltext 
082 0 |a 610 
520 |a The objective of this report was to perform a systematic review of the beneficial and harmful effects of a glecaprevir 100 mg / pibrentasvir 40 mg fixed-dose combination tablet for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults 

Similar Items